Quoc Le-Nguyen
Chief Tech/Sci/R&D Officer bei 89BIO, INC.
Vermögen: 3 Mio $ am 31.03.2024
Profil
Quoc Le-Nguyen is currently the Chief Technical Operations Officer & Head-Quality at 89bio, Inc. He previously worked as the Vice President-Manufacturing Operations at Bayer AG from 2007 to 2013 and as the SVP, Global Head-Technical Operations & Quality at Aduro BioTech, Inc. from 2015 to 2018.
Mr. Le-Nguyen completed his undergraduate degree at the University of California.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
89BIO INC
0,24% | 17.02.2024 | 222 149 ( 0,24% ) | 3 Mio $ | 31.03.2024 |
Aktive Positionen von Quoc Le-Nguyen
| Unternehmen | Position | Beginn |
|---|---|---|
| 89BIO, INC. | Chief Tech/Sci/R&D Officer | 01.03.2019 |
Ehemalige bekannte Positionen von Quoc Le-Nguyen
| Unternehmen | Position | Ende |
|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Corporate Officer/Principal | 01.07.2018 |
| BAYER AG | Corporate Officer/Principal | 01.09.2013 |
Ausbildung von Quoc Le-Nguyen
| University of California | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BAYER AG | Health Technology |
| 89BIO, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
